<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Unipolar major depression in adults: Augmentation of antidepressants with stimulants and stimulant-like drugs</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Unipolar major depression in adults: Augmentation of antidepressants with stimulants and stimulant-like drugs</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Unipolar major depression in adults: Augmentation of antidepressants with stimulants and stimulant-like drugs</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew Nierenberg, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter P Roy-Byrne, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Solomon, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 18, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H280588"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Stimulants (eg, <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a>) are primarily used to treat attention deficit hyperactivity disorder (ADHD), and stimulant-like drugs such as <a class="drug drug_general" data-topicid="10157" href="/z/d/drug information/10157.html" rel="external">modafinil</a> are used for narcolepsy, obstructive sleep apnea, and sleep shift work disorder [<a href="#rid1">1</a>]. However, stimulants have also been used for decades as add-on treatment in patients with unipolar major depression who have not responded adequately to antidepressant monotherapy [<a href="#rid2">2</a>]. In a retrospective study of patients with unipolar major depression who were treated with an antidepressant and then received augmentation therapy (n &gt;3200), stimulants were used in 5 percent of the patients [<a href="#rid3">3</a>].</p><p>This topic reviews the efficacy of stimulants and stimulant-like drugs for augmentation of antidepressants in treatment-resistant, unipolar major depression. Choosing a drug regimen for treatment-resistant depression is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14685.html" rel="external">"Unipolar depression in adults: Choosing treatment for resistant depression"</a>.)</p><p class="headingAnchor" id="H5504670"><span class="h1">RATIONALE</span><span class="headingEndMark"> — </span>Adjunctive therapy for unipolar major depression is often required because initial treatment with a single antidepressant leads to remission in only 30 to 50 percent of patients [<a href="#rid4">4-6</a>]. Options for add-on treatment include second-generation antipsychotics, <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>, triiodothyronine, a second antidepressant, and psychotherapy (eg, cognitive-behavioral therapy). It is also thought that stimulants and stimulant-like drugs may be useful for patients with treatment-resistant depression because these drugs may ameliorate symptoms such as anergia, fatigue, hypersomnia, and impaired concentration, which are often initial or residual symptoms of major depression as well as side effects of some antidepressants [<a href="#rid7">7,8</a>].</p><p>In addition, it is biologically plausible that stimulants may be of value for treating depression when combined with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). The pathophysiology of major depression may involve insufficient monoaminergic neurotransmission, and SSRIs initially increase serotonergic activity and SNRIs increase serotonergic and noradrenergic activity. However, major depression may also be associated with diminished dopaminergic transmission, and stimulants, <a class="drug drug_general" data-topicid="10157" href="/z/d/drug information/10157.html" rel="external">modafinil</a>, and <a class="drug drug_general" data-topicid="9560" href="/z/d/drug information/9560.html" rel="external">pramipexole</a> increase dopaminergic activity [<a href="#rid9">9-11</a>].</p><p class="headingAnchor" id="H280691"><span class="h1">INDICATIONS</span><span class="headingEndMark"> — </span>Stimulants (eg, <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a>) are indicated for late-life, treatment-resistant unipolar major depression. In addition, stimulant-like drugs (eg, <a class="drug drug_general" data-topicid="10157" href="/z/d/drug information/10157.html" rel="external">modafinil</a> and <a class="drug drug_general" data-topicid="9560" href="/z/d/drug information/9560.html" rel="external">pramipexole</a>) have limited evidence for efficacy in the general population of patients with treatment-resistant major depression. The use of stimulants and stimulant-like drugs is consistent with multiple treatment guidelines [<a href="#rid12">12-14</a>]. Based upon our clinical experience, we are more inclined to use stimulants and stimulant-like drugs for patients who lack energy, drive, motivation, interest, optimism, pleasure, and the ability to initiate activities [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H280698"><span class="h2">Contraindications</span><span class="headingEndMark"> — </span>Stimulants are generally contraindicated in patients with psychosis, persistent symptoms of anxiety or insomnia, comorbid anxiety disorders, or a history of substance use disorder that would require close monitoring of dosing and vigilance against escalating doses and misuse. Stimulants may also be contraindicated in patients with preexisting cardiovascular conditions [<a href="#rid1">1</a>]. If treatment-emergent mania occurs during pharmacotherapy with stimulants, the drugs should be discontinued abruptly.</p><p class="headingAnchor" id="H86123635"><span class="h1">DRUG-DRUG INTERACTIONS</span><span class="headingEndMark"> — </span>Drug-drug interactions may occur when stimulants or stimulant-like drugs are combined with antidepressants. Specific interactions may be determined using the <a class="external" href="/drug-interactions">drug interactions program</a> included in UpToDate.</p><p class="headingAnchor" id="H280722"><span class="h1">EFFICACY OF SPECIFIC DRUGS</span><span class="headingEndMark"> — </span>The evidence supporting the use of <a class="drug drug_general" data-topicid="10157" href="/z/d/drug information/10157.html" rel="external">modafinil</a> as adjunctive treatment is more compelling than that for stimulants or other stimulant-like drugs [<a href="#rid1">1</a>]. In addition, the evidence for stimulants as augmentation may be stronger for late-life depression than the general population of patients with treatment-resistant depression.</p><p class="headingAnchor" id="H5504677"><span class="h2">Stimulants</span><span class="headingEndMark"> — </span>For the general population of patients with treatment-resistant unipolar major depression, randomized trials generally indicate that the benefit of augmenting antidepressants with stimulants such as <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a> or <a class="drug drug_general" data-topicid="10143" href="/z/d/drug information/10143.html" rel="external">lisdexamfetamine</a> is limited at best, but can help alleviate some specific symptoms.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Methylphenidate</strong> – Add-on <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a> may possibly be useful in the general population of patients with treatment-resistant depression:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a five-week trial that compared adjunctive <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a> (extended release, 18 to 54 mg per day) with placebo in 145 patients who presented with treatment-resistant depression, improvement of the depressive syndrome (including apathy) was initially greater with methylphenidate than placebo [<a href="#rid16">16</a>]. However, at the end of treatment, improvement was comparable for the two groups.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A four-week trial compared extended release <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a> (18 to 54 mg per day) with placebo as adjunctive therapy in 60 patients who presented with treatment-resistant depression [<a href="#rid17">17</a>]. Symptomatic improvement was comparable for the two groups. However, response (reduction of baseline symptoms ≥50 percent) was larger with active drug than placebo (40 versus 23 percent). Although this difference was not statistically significant, a difference of this magnitude, if real, would be clinically meaningful.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lisdexamfetamine</strong> – Add-on <a class="drug drug_general" data-topicid="10143" href="/z/d/drug information/10143.html" rel="external">lisdexamfetamine</a> does not improve treatment-resistant depression. A meta-analysis of four randomized trials compared add-on lisdexamfetamine with placebo in patients (n = 971) who did not respond to initial monotherapy with <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">citalopram</a>, <a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">duloxetine</a>, <a class="drug drug_general" data-topicid="9046" href="/z/d/drug information/9046.html" rel="external">escitalopram</a>, <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a>, <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">paroxetine</a>, <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a>, or <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">venlafaxine</a> [<a href="#rid18">18</a>]. Improvement with adjunctive lisdexamfetamine and placebo was comparable.</p><p></p><p>Other smaller studies provide only indirect evidence supporting the use of adjunctive stimulants for treatment-resistant depression. A meta-analysis of three randomized trials compared stimulants with placebo as monotherapy in 62 depressed patients [<a href="#rid19">19</a>]. The trials lasted one to three weeks, and the stimulants consisted of pemoline 50 mg per day, <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a> 20 mg per day, or <a class="drug drug_general" data-topicid="9341" href="/z/d/drug information/9341.html" rel="external">dextroamphetamine</a> with a maximum dose of 40 mg per day. The analysis found a significant and large clinical effect favoring stimulant monotherapy over placebo.</p><p>Studies of stimulants for unipolar major depression usually omit evaluation of comorbid adult attention deficit hyperactivity disorder (ADHD). This is relevant because emotional dysregulation may be associated with adult ADHD, and there is an increased risk of depression in patients with ADHD [<a href="#rid20">20-22</a>]. In addition, the risk of ADHD is elevated in patients with unipolar depression compared with the general population. The assessment and diagnosis of ADHD in adults is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1232.html" rel="external">"Attention deficit hyperactivity disorder in adults: Epidemiology, clinical features, assessment, and diagnosis"</a>.)</p><p class="headingAnchor" id="H80862678"><span class="h3">Older patients</span><span class="headingEndMark"> — </span>Adjunctive stimulants may be useful for late-life, treatment-resistant depression that is accompanied by apathy, fatigue, or general medical illnesses [<a href="#rid23">23</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A 10-week randomized trial compared <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a> (mean daily dose 15 mg) plus <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">citalopram</a> with placebo plus citalopram in 16 patients (mean age 74 years) with major depression [<a href="#rid24">24</a>]. Most patients had chronic, recurrent, and treatment-resistant depression, and the study drug and citalopram were started concurrently. Improvement was greater with adjunctive methylphenidate than placebo.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A subsequent 16-week randomized trial by the same principal investigator enrolled patients (n = 143; mean age 70 years) with unipolar major depression who were free of psychotropic medications for at least two weeks, and assigned them to receive <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">citalopram</a> plus <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a>, citalopram plus placebo, or methylphenidate plus placebo [<a href="#rid25">25</a>]. Treatment-resistant depression was present in 41 percent of the sample. Citalopram doses ranged from 20 to 60 mg/day and methylphenidate from 5 to 40 mg/day. Improvement was greater and occurred more quickly with combination treatment than either citalopram monotherapy or methylphenidate monotherapy. In addition, discontinuation of treatment due to side effects appeared to be comparable for the three groups. It is worth noting that stimulants can lead to adverse cardiac effects, and that the maximum dose of citalopram recommended by the US Food and Drug Administration for patients aged &gt;60 years is 20 mg/day.</p><p></p><p>In addition, indirect evidence supporting the use of adjunctive stimulants includes a randomized trial that compared <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a> with placebo as monotherapy for major depression in older patients with general medical illnesses; methylphenidate was beneficial [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H80862275"><span class="h2">Modafinil and armodafinil</span><span class="headingEndMark"> — </span>For patients with treatment-resistant depression, augmentation of antidepressants with <a class="drug drug_general" data-topicid="10157" href="/z/d/drug information/10157.html" rel="external">modafinil</a> can be useful, and modafinil lacks many of the undesirable effects of stimulants, including cardiovascular risks and the potential for abuse [<a href="#rid11">11</a>].</p><p>Evidence supporting the use of adjunctive <a class="drug drug_general" data-topicid="10157" href="/z/d/drug information/10157.html" rel="external">modafinil</a> includes randomized trials. As an example, a meta-analysis of three trials lasting six or eight weeks compared adjunctive modafinil (100 to 400 mg per day) with placebo in 522 patients with unipolar major depression [<a href="#rid7">7</a>]. The majority of patients were partial responders to initial treatment with antidepressant monotherapy (primarily SSRIs), and the remaining patients received augmentation from the beginning of treatment. The analysis found a significant, but clinically small effect favoring modafinil over placebo. In the largest study, nausea and feeling jittery were more common with modafinil than placebo [<a href="#rid27">27</a>].</p><p>In addition, augmentation with <a class="drug drug_general" data-topicid="10157" href="/z/d/drug information/10157.html" rel="external">modafinil</a> may perhaps be useful for patients who have recovered from an episode of depression but still have impaired memory. A proof-of-concept (pilot) randomized trial compared a single dose of add-on modafinil (200 mg) with placebo in 60 patients with remitted unipolar depression who still had some degree of residual depressive symptoms, including cognitive dysfunction [<a href="#rid28">28</a>]. Improvement of memory was greater with modafinil than placebo.</p><p>Longer treatment with <a class="drug drug_general" data-topicid="10157" href="/z/d/drug information/10157.html" rel="external">modafinil</a> may also be useful. A 12-week prospective observational study followed patients with treatment-resistant, unipolar major depression who responded to modafinil in a randomized trial (n = 57) [<a href="#rid29">29</a>]. Improvement of depression that accrued during the randomized trial persisted during the observational study.</p><p><a class="drug drug_general" data-topicid="9260" href="/z/d/drug information/9260.html" rel="external">Armodafinil</a> is the R enantiomer of racemic <a class="drug drug_general" data-topicid="10157" href="/z/d/drug information/10157.html" rel="external">modafinil</a>, and the half-life of armodafinil is longer than that for modafinil. Although armodafinil has not been studied in unipolar major depression, it is probably effective for this indication, based upon the demonstrated efficacy of modafinil [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H248502038"><span class="h2">Pramipexole</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9560" href="/z/d/drug information/9560.html" rel="external">Pramipexole</a> may be beneficial as augmentation for unipolar major depression. An eight-week randomized trial compared pramipexole (mean daily dose 1.35 mg) with placebo as add-on treatment in 60 patients who remained depressed despite treatment with a selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor [<a href="#rid30">30</a>]. Improvement was greater with pramipexole, and the frequency of specific adverse effects was generally comparable for the two groups.</p><p>Although a second trial found that the combination of <a class="drug drug_general" data-topicid="9560" href="/z/d/drug information/9560.html" rel="external">pramipexole</a> and an antidepressant was not effective for treatment-resistant depression, the negative results may have been attributable to the study methods. The six-week trial randomly assigned patients who had not responded to an antidepressant (n = 39) to receive pramipexole alone, <a class="drug drug_general" data-topicid="9046" href="/z/d/drug information/9046.html" rel="external">escitalopram</a> alone, or the combination of escitalopram and pramipexole [<a href="#rid31">31</a>]. Improvement was greater with pramipexole monotherapy than combination therapy. Most patients in the combination therapy group could not tolerate the dose titration schedule for pramipexole, and discontinuation of treatment was greater with combination treatment (9/13, 69 percent) than pramipexole alone (2/13, 15 percent) or escitalopram alone (2/13, 15 percent). Concurrently starting pramipexole and escitalopram (rather than adding pramipexole to an established therapeutic dose) may have led to the high dropout rate. In addition, the small number of study patients makes it difficult to interpret the results.</p><p>Indirect evidence supporting the use of adjunctive <a class="drug drug_general" data-topicid="9560" href="/z/d/drug information/9560.html" rel="external">pramipexole</a> for treating depression includes an eight-week randomized trial that compared pramipexole (1 mg per day) with placebo as monotherapy for the initial treatment of 70 patients with unipolar major depression [<a href="#rid32">32</a>]. Improvement was greater with pramipexole than placebo.</p><p class="headingAnchor" id="H248502052"><span class="h2">Atomoxetine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8787" href="/z/d/drug information/8787.html" rel="external">Atomoxetine</a> is a noradrenergic drug that is used to treat ADHD, but does not appear to be useful as add-on treatment for depression. An eight-week randomized trial compared atomoxetine (40 to 120 mg per day) with placebo as augmentation in 146 patients with unipolar major depression who did not respond satisfactorily to <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a> monotherapy [<a href="#rid33">33</a>]. Remission was comparable for adjunctive atomoxetine and placebo (40 and 38 percent of patients).</p><p class="headingAnchor" id="H5504684"><span class="h2">Other dopaminergic agents</span><span class="headingEndMark"> — </span>Low-quality evidence suggests that <a class="drug drug_general" data-topicid="8508" href="/z/d/drug information/8508.html" rel="external">amantadine</a>, <a class="drug drug_general" data-topicid="9164" href="/z/d/drug information/9164.html" rel="external">bromocriptine</a>, pergolide, and <a class="drug drug_general" data-topicid="10246" href="/z/d/drug information/10246.html" rel="external">ropinirole</a> may possibly be useful as augmentation for treatment-resistant unipolar major depression [<a href="#rid34">34-41</a>].</p><p class="headingAnchor" id="H1515196521"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116503.html" rel="external">"Society guideline links: Depressive disorders"</a>.)</p><p class="headingAnchor" id="H5504698"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Stimulants and stimulant-like drugs may be useful for patients with treatment-resistant depression because these drugs may ameliorate symptoms such as anergia, fatigue, hypersomnia, executive dysfunction, impaired memory, and impaired concentration, which are often symptoms of major depression as well as side effects of some antidepressants. (See <a class="local">'Rationale'</a> above and <a class="local">'Efficacy of specific drugs'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stimulants (eg, <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a>) are indicated for late-life, treatment-resistant depression. In addition, stimulant-like drugs (eg, <a class="drug drug_general" data-topicid="10157" href="/z/d/drug information/10157.html" rel="external">modafinil</a> and <a class="drug drug_general" data-topicid="9560" href="/z/d/drug information/9560.html" rel="external">pramipexole</a>) have limited evidence for efficacy in the general population of patients with treatment-resistant unipolar major depression. (See <a class="local">'Indications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stimulants are generally contraindicated in patients with psychosis, persistent symptoms of anxiety or insomnia, comorbid anxiety disorders, or a history of substance use disorder. (See <a class="local">'Contraindications'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Corp SA, Gitlin MJ, Altshuler LL. A review of the use of stimulants and stimulant alternatives in treating bipolar depression and major depressive disorder. J Clin Psychiatry 2014; 75:1010.</a></li><li><a class="nounderline abstract_t">Bahji A, Mesbah-Oskui L. Comparative efficacy and safety of stimulant-type medications for depression: A systematic review and network meta-analysis. J Affect Disord 2021; 292:416.</a></li><li><a class="nounderline abstract_t">Gersing KR, Sheehan JJ, Burchett B, et al. Use of augmentation agents for treating depression: analysis of a psychiatric electronic medical record data set. Psychiatr Serv 2014; 65:1062.</a></li><li><a class="nounderline abstract_t">Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163:28.</a></li><li><a class="nounderline abstract_t">Thase ME, Haight BR, Richard N, et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 2005; 66:974.</a></li><li><a class="nounderline abstract_t">Thase ME, Nierenberg AA, Vrijland P, et al. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. Int Clin Psychopharmacol 2010; 25:189.</a></li><li><a class="nounderline abstract_t">Goss AJ, Kaser M, Costafreda SG, et al. Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry 2013; 74:1101.</a></li><li class="breakAll">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.</li><li><a class="nounderline abstract_t">Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 2007; 64:327.</a></li><li><a class="nounderline abstract_t">Papakostas GI. Dopaminergic-based pharmacotherapies for depression. Eur Neuropsychopharmacol 2006; 16:391.</a></li><li><a class="nounderline abstract_t">Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology 2008; 33:1477.</a></li><li><a class="nounderline abstract_t">American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder, third edition. Am J Psychiatry 2010; 167 (supplement):1.</a></li><li class="breakAll">American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Third Edition, 2010. http://www.psychiatry.org/practice/clinical-practice-guidelines (Accessed on October 04, 2014).</li><li><a class="nounderline abstract_t">Lam RW, Kennedy SH, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 2009; 117 Suppl 1:S26.</a></li><li><a class="nounderline abstract_t">Orr K, Taylor D. Psychostimulants in the treatment of depression : a review of the evidence. CNS Drugs 2007; 21:239.</a></li><li><a class="nounderline abstract_t">Ravindran AV, Kennedy SH, O'Donovan MC, et al. Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 2008; 69:87.</a></li><li><a class="nounderline abstract_t">Patkar AA, Masand PS, Pae CU, et al. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. J Clin Psychopharmacol 2006; 26:653.</a></li><li><a class="nounderline abstract_t">Giacobbe P, Rakita U, Lam R, et al. Efficacy and tolerability of lisdexamfetamine as an antidepressant augmentation strategy: A meta-analysis of randomized controlled trials. J Affect Disord 2018; 226:294.</a></li><li><a class="nounderline abstract_t">Candy M, Jones L, Williams R, et al. Psychostimulants for depression. Cochrane Database Syst Rev 2008; :CD006722.</a></li><li><a class="nounderline abstract_t">Reimherr FW, Marchant BK, Strong RE, et al. Emotional dysregulation in adult ADHD and response to atomoxetine. Biol Psychiatry 2005; 58:125.</a></li><li><a class="nounderline abstract_t">Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006; 163:716.</a></li><li><a class="nounderline abstract_t">Kessler RC, Adler LA, Barkley R, et al. Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication. Biol Psychiatry 2005; 57:1442.</a></li><li><a class="nounderline abstract_t">Hardy SE. Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults. Am J Geriatr Pharmacother 2009; 7:34.</a></li><li><a class="nounderline abstract_t">Lavretsky H, Park S, Siddarth P, et al. Methylphenidate-enhanced antidepressant response to citalopram in the elderly: a double-blind, placebo-controlled pilot trial. Am J Geriatr Psychiatry 2006; 14:181.</a></li><li><a class="nounderline abstract_t">Lavretsky H, Reinlieb M, St Cyr N, et al. Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2015; 172:561.</a></li><li><a class="nounderline abstract_t">Wallace AE, Kofoed LL, West AN. Double-blind, placebo-controlled trial of methylphenidate in older, depressed, medically ill patients. Am J Psychiatry 1995; 152:929.</a></li><li><a class="nounderline abstract_t">Fava M, Thase ME, DeBattista C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry 2005; 66:85.</a></li><li><a class="nounderline abstract_t">Kaser M, Deakin JB, Michael A, et al. Modafinil Improves Episodic Memory and Working Memory Cognition in Patients With Remitted Depression: A Double-Blind, Randomized, Placebo-Controlled Study. Biol Psychiatry Cogn Neurosci Neuroimaging 2017; 2:115.</a></li><li><a class="nounderline abstract_t">Thase ME, Fava M, DeBattista C, et al. Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study. CNS Spectr 2006; 11:93.</a></li><li><a class="nounderline abstract_t">Cusin C, Iovieno N, Iosifescu DV, et al. A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder. J Clin Psychiatry 2013; 74:e636.</a></li><li><a class="nounderline abstract_t">Franco-Chaves JA, Mateus CF, Luckenbaugh DA, et al. Combining a dopamine agonist and selective serotonin reuptake inhibitor for the treatment of depression: a double-blind, randomized pilot study. J Affect Disord 2013; 149:319.</a></li><li><a class="nounderline abstract_t">Corrigan MH, Denahan AQ, Wright CE, et al. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 2000; 11:58.</a></li><li><a class="nounderline abstract_t">Michelson D, Adler LA, Amsterdam JD, et al. Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007; 68:582.</a></li><li><a class="nounderline abstract_t">Cassano P, Lattanzi L, Fava M, et al. Ropinirole in treatment-resistant depression: a 16-week pilot study. Can J Psychiatry 2005; 50:357.</a></li><li><a class="nounderline abstract_t">Wada T, Kanno M, Aoshima T, Otani K. Dose-dependent augmentation effect of bromocriptine in a case with refractory depression. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25:457.</a></li><li><a class="nounderline abstract_t">Inoue T, Tsuchiya K, Miura J, et al. Bromocriptine treatment of tricyclic and heterocyclic antidepressant-resistant depression. Biol Psychiatry 1996; 40:151.</a></li><li><a class="nounderline abstract_t">McGrath PJ, Quitkin FM, Klein DF. Bromocriptine treatment of relapses seen during selective serotonin re-uptake inhibitor treatment of depression. J Clin Psychopharmacol 1995; 15:289.</a></li><li><a class="nounderline abstract_t">Bouras N, Bridges PK. Bromocriptine in depression. Curr Med Res Opin 1982; 8:150.</a></li><li><a class="nounderline abstract_t">Goforth H. Amantadine in catatonia due to major depressive disorder in a medically ill patient. J Neuropsychiatry Clin Neurosci 2007; 19:480.</a></li><li><a class="nounderline abstract_t">Quarantini LC, Miranda-Scippa A, Schinoni MI, et al. Effect of amantadine on depressive symptoms in chronic hepatitis C patients treated with pegylated interferon: a randomized, controlled pilot study. Clin Neuropharmacol 2006; 29:138.</a></li><li><a class="nounderline abstract_t">Izumi T, Inoue T, Kitagawa N, et al. Open pergolide treatment of tricyclic and heterocyclic antidepressant-resistant depression. J Affect Disord 2000; 61:127.</a></li></ol></div><div id="topicVersionRevision">Topic 14676 Version 13.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25295426" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : A review of the use of stimulants and stimulant alternatives in treating bipolar depression and major depressive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34144366" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Comparative efficacy and safety of stimulant-type medications for depression: A systematic review and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24932958" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Use of augmentation agents for treating depression: analysis of a psychiatric electronic medical record data set.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16390886" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16086611" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20531012" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24330897" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24330897" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17339521" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The role of dopamine in the pathophysiology of depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16413172" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Dopaminergic-based pharmacotherapies for depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17712350" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Modafinil: a review of neurochemical actions and effects on cognition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Practice Guideline for the Treatment of Patients with Major Depressive Disorder, third edition</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Practice Guideline for the Treatment of Patients with Major Depressive Disorder, third edition</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19674794" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17338594" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Psychostimulants in the treatment of depression : a review of the evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18312042" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17110825" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29028590" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Efficacy and tolerability of lisdexamfetamine as an antidepressant augmentation strategy: A meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18425966" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Psychostimulants for depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16038683" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Emotional dysregulation in adult ADHD and response to atomoxetine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16585449" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15950019" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19281939" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16473984" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Methylphenidate-enhanced antidepressant response to citalopram in the elderly: a double-blind, placebo-controlled pilot trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25677354" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7755127" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Double-blind, placebo-controlled trial of methylphenidate in older, depressed, medically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15669893" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28299368" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Modafinil Improves Episodic Memory and Working Memory Cognition in Patients With Remitted Depression: A Double-Blind, Randomized, Placebo-Controlled Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16520686" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23945458" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23517885" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Combining a dopamine agonist and selective serotonin reuptake inhibitor for the treatment of depression: a double-blind, randomized pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10812530" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Comparison of pramipexole, fluoxetine, and placebo in patients with major depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17474814" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15999953" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Ropinirole in treatment-resistant depression: a 16-week pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11294489" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Dose-dependent augmentation effect of bromocriptine in a case with refractory depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8793048" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Bromocriptine treatment of tricyclic and heterocyclic antidepressant-resistant depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7593717" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Bromocriptine treatment of relapses seen during selective serotonin re-uptake inhibitor treatment of depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7128188" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Bromocriptine in depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18070864" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Amantadine in catatonia due to major depressive disorder in a medically ill patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16772812" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Effect of amantadine on depressive symptoms in chronic hepatitis C patients treated with pegylated interferon: a randomized, controlled pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11099751" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Open pergolide treatment of tricyclic and heterocyclic antidepressant-resistant depression.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
